Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Global Cord Blood ( (CORBF) ) has provided an announcement.
On March 3, 2025, the joint provisional liquidators (JPLs) of Global Cord Blood Corporation submitted their eleventh report to the Grand Court of the Cayman Islands. The appointment of the JPLs was initially ordered on September 22, 2022, as part of the company’s ongoing liquidation process. The report is part of a series of updates provided to the court, reflecting the company’s current status and ongoing proceedings. This development is significant as it continues to impact the company’s operations and its stakeholders, highlighting the challenges faced in the cord blood banking industry.
More about Global Cord Blood
Global Cord Blood Corporation operates in the healthcare industry, focusing primarily on the storage and preservation of umbilical cord blood stem cells. The company is positioned within the niche market of cord blood banking, providing services that are crucial for medical treatments and research.
YTD Price Performance: -20.79%
Average Trading Volume: 8,392
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $107.1M
See more insights into CORBF stock on TipRanks’ Stock Analysis page.